Safety and pharmacokinetics of plasma-derived mannose-binding lectin (MBL) substitution in children with chemotherapy-induced neutropaenia

This publication has 24 references indexed in Scilit:

• Low mannose-binding lectin (MBL) levels in neonates with pneumonia and sepsis
  Clinical and Experimental Immunology, 2007
• Mannan-binding lectin (MBL)-mediated opsonization is enhanced by the alternative pathway amplification loop
  Molecular Immunology, 2006
• The role of mannose-binding lectin (MBL) in paediatric oncology patients with febrile neutropenia
  European Journal Of Cancer, 2006
• Infections during induction therapy of childhood acute lymphoblastic leukemia – no association to mannose‐binding lectin deficiency
  European Journal of Haematology, 2006
• Characterization of the Oligomer Structure of Recombinant Human Mannan-binding Lectin
  Journal of Biological Chemistry, 2005
• Human Plasma-Derived Mannose-Binding Lectin: A Phase I Safety and Pharmacokinetic Study
  Scandinavian Journal of Immunology, 2004
• Mannose‐binding lectin (MBL) therapy in an MBL‐deficient patient with severe cystic fibrosis lung disease
  Pediatric Pulmonology, 2002
• Reconstitution of Opsonizing Activity by Infusion of Mannan‐Binding Lectin (MBL) to MBL‐Deficient Humans
  Scandinavian Journal of Immunology, 1998
• Mannose-binding lectin: the pluripotent molecule of the innate immune system
  Immunology Today, 1996
• The importance of modeling interoccasion variability in population pharmacokinetic analyses
  Journal of Pharmacokinetics and Biopharmaceutics, 1993